Danaher Co. (NYSE:DHR) Shares Bought by Dixon Mitchell Investment Counsel Inc.

Dixon Mitchell Investment Counsel Inc. lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 131,440 shares of the conglomerate’s stock after buying an additional 6,688 shares during the period. Danaher makes up approximately 1.7% of Dixon Mitchell Investment Counsel Inc.’s holdings, making the stock its 25th largest position. Dixon Mitchell Investment Counsel Inc.’s holdings in Danaher were worth $36,578,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Tsfg LLC raised its stake in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC purchased a new position in Danaher during the 2nd quarter worth $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the 1st quarter worth $30,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Danaher in the second quarter valued at about $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on DHR shares. Wells Fargo & Company initiated coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Barclays upped their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Leerink Partners raised their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Finally, Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Stock Performance

NYSE DHR opened at $274.33 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business has a fifty day moving average of $270.72 and a 200-day moving average of $259.92. The stock has a market cap of $203.19 billion, a price-to-earnings ratio of 46.50, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. As a group, analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.